Aspire Biopharma Holdings (ASBP) Common Equity (2021 - 2026)
Aspire Biopharma Holdings (ASBP) posted quarterly Common Equity of $3.9 million for Q1 2026, up 148.64% year-over-year from $1.6 million in Q1 2025, and up 160.67% quarter-over-quarter from -$6.4 million in Q4 2025.
Aspire Biopharma Holdings (ASBP) Common Equity (2021 - 2026) Analysis & Trends
Aspire Biopharma Holdings (ASBP) has reported Common Equity for 6 consecutive years, with $3.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Common Equity rose 148.64% year-over-year to $3.9 million; the TTM figure through Mar 2026 stood at $3.9 million (up 148.64% YoY), while the FY2025 annual figure was -$6.4 million, down 314.02% from the prior year.
- Common Equity rose to $3.9 million in Q1 2026 per ASBP's latest filing, from -$6.4 million in the prior quarter.
- Across five years, Common Equity topped out at $3.9 million in Q1 2026 and bottomed at -$11.5 million in Q3 2025.
- Historically, Common Equity has averaged -$4.9 million across 5 years, with a median of -$6.4 million in 2025.
- Annual changes were most pronounced in 2022 — Common Equity plunged 3437196.79% — and 2026, when it soared 148.64%.
- Aspire Biopharma Holdings' Common Equity stood at -$9.9 million in 2022, then soared by 95.09% to -$487861.0 in 2023, then tumbled by 215.68% to -$1.5 million in 2024, then tumbled by 314.02% to -$6.4 million in 2025, then surged by 160.67% to $3.9 million in 2026.
- Business Quant data shows ASBP's Common Equity at $3.9 million in Q1 2026, -$6.4 million in Q4 2025, and -$11.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.79 Bn |
| 10 | Aspire Biopharma Holdings | 8.30 Mn | -3.86 Mn | -30,086.00 | 11.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 11.76 Mn |
| Mar 31, 2026 | 3.87 Mn |
| Dec 31, 2025 | -6.38 Mn |
| Sep 30, 2025 | -11.47 Mn |
| Jun 30, 2025 | -9.62 Mn |
| Mar 31, 2025 | -7.95 Mn |
| Dec 31, 2024 | -1.54 Mn |
| Sep 30, 2024 | -774,378.00 |
| Jun 30, 2024 | -558,109.00 |
| Mar 31, 2024 | -489,747.00 |
| Dec 31, 2023 | -487,861.00 |
| Sep 30, 2023 | -62,954.00 |
| Jun 30, 2023 | 261,788.00 |
| Mar 31, 2023 | -10.26 Mn |
| Dec 31, 2022 | -9.94 Mn |
| Sep 30, 2022 | -9.62 Mn |
| Jun 30, 2022 | -9.37 Mn |
| Mar 31, 2022 | -9.05 Mn |
| Dec 31, 2021 | -475.00 |
| Sep 30, 2021 | 280.00 |